VIP (Vasoactive Intestinal Peptide): Research

• VIP is a 28-amino-acid neuropeptide found in many tissues, not just the gut.
• Research links VIP to immune control, barrier function, vascular tone, and glucose regulation.
• Human infusion studies showed rapid breakdown, with an average disappearance half-time of about one minute.
• Most interest today is in VIP signaling pathways, not in treating VIP as a simple circulating hormone.

What VIP is

Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid neuropeptide. It was identified in the early 1970s. Early work found VIP in neural tissue, and later work showed it appears across multiple body systems. The name points to the gut, but the biology is broader than that. VIP has been described as part of the body’s neuro-immune-gut axis because it helps coordinate signals between the nervous system, immune system, and organs such as the gut, lungs, pancreas, heart, and blood vessels.

That wide distribution matters. VIP does not act like a single-purpose molecule. It helps regulate how tissues respond to stress, inflammation, and injury. In research summaries, it is often described as a systems-level signal rather than a local-only gut peptide.

Where it acts

VIP signals through two main receptors, VPAC1 and VPAC2. These receptors are found in many tissues, including immune cells and organs involved in vascular and metabolic control. Because these receptors are widely expressed, VIP can affect more than one biological pathway at the same time.

That broad reach is one reason VIP shows up in research on inflammation, intestinal function, airway biology, neurobiology, and glucose homeostasis.

Immune regulation

One of the clearest themes in the research is immune modulation. VIP has been described as a potent anti-inflammatory neuropeptide. The research bundle links VIP signaling with lower levels of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-12, along with higher IL-10 and increased regulatory T-cell activity. It is also associated with reduced Th1 and Th17 activity.

That profile matters because immune balance is not just about turning inflammation off. It is about keeping immune responses strong enough to defend the body, but not so strong that they drive chronic tissue damage. VIP is often discussed in that context: as a signal that may support immune tolerance and limit excess inflammation.

What animal data show

A mouse study in hematologic cancer models tested a VIP-pathway antagonist called VIPhyb. Blocking the VIP pathway enhanced a T-cell-dependent anti-leukemia response. In that study, subcutaneous VIPhyb reduced tumor burden and improved survival to 30-50%, compared with 0-20% in vehicle controls. The T cells from treated mice also showed lower PD-1 levels and higher IFNγ secretion. That does not mean VIP is “good” or “bad.” It means the pathway can shape immune tone in a meaningful way.

This is an important point for interpretation. VIP’s anti-inflammatory behavior can be helpful in one context and potentially limiting in another. The leukemia work suggests that dampening VIP signaling may increase anti-tumor immune activity in some models. That is a different question from whether VIP helps resolve inflammatory disease.

Why this matters for research

VIP sits near the center of immune regulation, but the direction of effect depends on context. A pathway that reduces damaging inflammation may also reduce immune aggression against tumors or other targets. That makes VIP a useful research target, but also a complex one.

Gut and barrier function

VIP is strongly connected to gut biology. The research bundle describes it as part of the gut integrity network and links low or dysfunctional VIP signaling with gut permeability. In plain terms, this means VIP is often discussed in relation to the intestinal barrier, inflammation in the gut, and communication between the gut and the nervous system.

That fits with older and newer work alike. The name “vasoactive intestinal peptide” reflects early interest in gut and vascular effects, but current research places VIP in a larger communication network that includes epithelial integrity and immune signaling.

What the older human work suggests

In a human infusion study, graded doses of 0.6, 1.3, and 3.3 pmol/kg/min were given to healthy volunteers over 30 minutes. Even the smallest dose raised plasma VIP markedly above normal values. Higher doses produced plasma levels similar to those seen in Verner-Morrison syndrome. After the infusion stopped, plasma VIP fell with an average disappearance half-time of about one minute.

The same study reported small but significant rises in glucose, free fatty acids, and calcium, along with increased pulse rate, higher blood pressure amplitude, and flushing at the highest dose. The authors concluded that the data did not support a major role for VIP as a circulating hormone under physiological conditions. That is a useful caution. VIP may be highly active biologically, but its normal behavior in the body is not the same as a classic long-lived blood hormone.

What that means in practice

The rapid breakdown of VIP helps explain why the pathway is usually discussed in terms of local signaling, receptor activity, and tissue-specific effects rather than simple blood levels. For researchers, that means dose, timing, route, and target tissue matter a great deal.

Nervous system and neurovascular roles

VIP is also active in the nervous system. Research cited in the bundle describes it as a neuropeptide with roles in autonomic regulation, and older literature links it to neural tissue distribution. Some sources describe it as influencing neurovascular health and brain-related signaling.

There is also research connecting VIP-related interneurons with goal-oriented spatial learning in the hippocampus. Other cited work places VIP in neural circuits of the amygdala and in broader studies of neuroprotection. This does not prove a single clinical effect. It does show that VIP is part of brain signaling systems tied to learning, emotion, and tissue protection.

Respiratory and vascular context

VIP has been studied in the respiratory tract and in vascular responses. In the human infusion study, pulse rate and blood pressure amplitude changed, and flushing occurred at the highest dose. That is consistent with a peptide that can influence vascular tone. The “vasoactive” part of the name is not decorative; it reflects real physiology.

Glucose homeostasis and pancreas research

VIP also appears in metabolic research. A 2022 review in Frontiers in Endocrinology reported that VIP can stimulate glucose-dependent insulin secretion, especially through VPAC2 receptors. The review also noted that VIP may promote islet beta-cell proliferation through the forkhead box M1 pathway.

That same review made two practical points. First, the potential of VIP in glucose control is interesting. Second, clinical use is limited by VIP’s short half-life and broad distribution in the body. Those limits help explain why researchers have also explored VPAC2-selective agonists as candidate hypoglycemic drugs.

Why selectivity matters

Because VIP acts through more than one receptor and in many tissues, a direct full-body approach may create side effects or unwanted effects. Receptor-selective strategies try to keep the useful parts of the signaling while reducing the rest. That is a common theme in peptide research, and VIP is no exception.

How researchers frame VIP today

Recent writing in the research bundle presents VIP as a broad regulator of immune balance, gut integrity, and neurovascular health. That framing is consistent with the older experimental literature, but it should be read carefully. It is not a claim that VIP fixes all those systems. It is a statement that VIP sits at an important intersection between them.

The same bundle also notes that low or dysfunctional VIP signaling is associated with chronic inflammatory illness, gut permeability, immune dysregulation, and neurologic symptoms. Association is not the same as proof of cause. Still, the pattern helps explain why VIP keeps attracting attention in integrative, endocrine, immunology, and neurobiology circles.

What is solid, and what is still open

What looks solid is the core biology: VIP is a 28-amino-acid peptide with known receptors, fast clearance, vascular effects, immune effects, and a wide tissue distribution. What remains open is how best to use that knowledge in humans. The research points to promise in some settings and caution in others.

The leukemia antagonist study is a good example. In one disease context, blocking VIP signaling improved anti-tumor immunity in mice. In other contexts, preserving or restoring VIP signaling may be the more relevant goal. The pathway is not one-dimensional.

What VIP does not yet prove

The current research does not justify simple conclusions like “more VIP is always better” or “VIP is only anti-inflammatory.” The human infusion study shows rapid metabolism and acute physiologic effects. The mouse leukemia data show that blocking VIP can improve some immune outcomes. The diabetes review shows possible metabolic value, but also clear limits to direct use. Put together, these studies show a pathway with real biological weight, but not a one-size-fits-all answer.

That is the right frame for VIP research: useful, wide-ranging, and still incomplete.

FAQ

What is VIP?

VIP, or vasoactive intestinal peptide, is a 28-amino-acid neuropeptide found in many tissues. It acts through VPAC1 and VPAC2 receptors and helps regulate immune, gut, vascular, nervous, and metabolic functions.

Why is VIP called a “master regulator”?

That phrase is used because VIP influences several systems at once. It can affect immune signaling, barrier function, blood vessels, and nerve-related communication. The term reflects its breadth, not a claim that it controls everything.

What did human infusion studies show?

In healthy volunteers, even a small infusion dose raised plasma VIP above normal. The peptide cleared quickly, with an average disappearance half-time of about one minute. Higher doses caused mild changes in glucose, free fatty acids, calcium, pulse rate, blood pressure amplitude, and flushing.

Is VIP always anti-inflammatory?

No. VIP is often described as anti-inflammatory, but the effect depends on context. In a mouse leukemia model, blocking the VIP pathway improved anti-tumor immune activity. That shows the pathway can be helpful to preserve or useful to block, depending on the goal.

What is the main research interest in VIP now?

Current research focuses on immune balance, gut integrity, neurovascular signaling, and glucose homeostasis. There is also interest in receptor-selective strategies, especially around VPAC2, because direct VIP use is limited by its short half-life and broad distribution.